BioCentury
ARTICLE | Clinical News

LR769: Completed Phase III enrollment

January 12, 2015 8:00 AM UTC

LFB S.A., Les Ulis, France Product: LR769 Business: Hematology Molecular target: Factor VIIa Description: Recombinant human Factor VIIa (rhFVIIa) Indication: Treat congenital hemophilia A and Beta En...